iQure Pharma Inc. (iQure), a US-based global biotech company, has confirmed through preclinical screenings that iQ-007, a novel anticonvulsant and analgesic compound, showed no binding to targets in the drug abuse potential panel.
Princeton, NJ, November 15, 2022 ─ iQure Pharma Inc. (iQure), a US-based global biotech company, has confirmed through preclinical screenings that iQ-007, a novel anticonvulsant and analgesic compound, showed no binding to targets in the drug abuse potential panel.
In line with the FDA guidance document, “Assessment of abuse potential of drugs” from January 2017, a full set of 44 potential targets were tested against a high dose of 100 uM of iQ-007 and no relevant binding was observed.
“This is very good news and an important step in the continued development of iQ-007 as a promising therapeutic,” said iQure Chief Operating Officer Henk de Wilde. “With so many drugs in the epilepsy and pain area showing abuse potential, it is comforting to know that iQ-007 shows no potential for abuse and truly is a non-opioid therapeutic.”
About iQure Pharma
A global biotech firm headquartered in Princeton, New Jersey, iQure Pharma is focused on the development of new therapeutics for CNS, including neuropathic pain, epilepsy and other neurodegenerative diseases. iQure researchers, clinicians, and pharmaceutical professionals work closely with academic partners, industry experts, and patient organizations to build medically and socially beneficial therapies. For more information about supporting iQure’s initiatives, contact iQure CFO Dr. Anna Rzewuska at anna.rzewuska@iqurepharma.com.